作者
Alejandro Martin-Montalvo, Evi M Mercken, Sarah J Mitchell, Hector H Palacios, Patricia L Mote, Morten Scheibye-Knudsen, Ana P Gomes, Theresa M Ward, Robin K Minor, Marie-José Blouin, Matthias Schwab, Michael Pollak, Yongqing Zhang, Yinbing Yu, Kevin G Becker, Vilhelm A Bohr, Donald K Ingram, David A Sinclair, Norman S Wolf, Stephen R Spindler, Michel Bernier, Rafael De Cabo
发表日期
2013/7/30
期刊
Nature communications
卷号
4
期号
1
页码范围
2192
出版商
Nature Publishing Group UK
简介
Metformin is a drug commonly prescribed to treat patients with type 2 diabetes. Here we show that long-term treatment with metformin (0.1% w/w in diet) starting at middle age extends healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic. Treatment with metformin mimics some of the benefits of calorie restriction, such as improved physical performance, increased insulin sensitivity, and reduced low-density lipoprotein and cholesterol levels without a decrease in caloric intake. At a molecular level, metformin increases AMP-activated protein kinase activity and increases antioxidant protection, resulting in reductions in both oxidative damage accumulation and chronic inflammation. Our results indicate that these actions may contribute to the beneficial effects of metformin on healthspan and lifespan. These findings are in agreement with current epidemiological data and raise the possibility of …
引用总数
20132014201520162017201820192020202120222023202477510412010812916215116517516465
学术搜索中的文章
A Martin-Montalvo, EM Mercken, SJ Mitchell… - Nature communications, 2013